Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISNU-2: FOLFIRI + Bevacizumab or Cetuximab in RAS Wild-type Metastatic Colorectal Cancer
NCT01640444Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jul 2012
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, KL-140 in metastatic colorectal cancer (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Started Jul 2012; status: completed.
02
Drugs
bevacizumabKL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01640444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640444.